611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Excess Weight May Raise Rosacea RiskDecline in Antibiotic Use in Livestock Isn't Enough, Critics SayCould a Hot Cup of Tea Preserve Your Vision?Breathing Retraining Beneficial in Patients With AsthmaZika Babies Facing Increasing Health Problems With AgeHealth Tip: Dental Association Supports Fluoridated WaterAnother Legacy of Terror Attacks: MigrainesRain May Not Cause Achy Joints After AllDisrupted Sleep Linked to Increased Amyloid-β ProductionAtherosclerosis ID'd in Many Without CV Risk FactorsArtificial Intelligence Promising for CA, Retinopathy DiagnosesFirst Drug Approved for Rare Condition That Inflames Blood VesselsProtecting Your Health From Wildfire SmokeHealth Tip: Recognize Warning Signs of HypothermiaNew Hope for Kids With Multiple Food AllergiesFew Patients, Providers Discuss Costs of Glaucoma Medicationsβ-Cell Sensitivity to Glucose Impaired After Gastric BypassHow to Perk Up the Holidays for Hospital PatientsVigorous Exercise May Help Slow Parkinson's DiseaseIf Mom Has Rheumatoid Arthritis, Baby May Develop It, TooNew Gene Therapy May Be Cure for 'Bubble Boy' DiseaseAnother Gene Therapy Breakthrough Against HemophiliaPrenatal Sugar Intake May Increase Asthma Risk in OffspringObesity May Be Tied to Higher Rosacea Risk in WomenGot Scabies? Here's What to DoAre Women With Parkinson's at a Disadvantage?Bariatric Surgery Alters Liver Fatty Acid MetabolismORBIT Bleeding Risk Score Performs Best in A-FibHealth Tip: Prevent the Spread of NorovirusAre Good Kidneys Going to Waste?Metabolic Risk Factors Linked to Severe Liver DiseaseImpaired White Matter Integrity for Depression in Parkinson'sHave Eczema? No Need for Bleach Baths, Study SuggestsPowerful Clot-Busting Drugs Not Useful After Leg Blockages: StudyComing Soon: A Gel That Could Help Save Soldiers' EyesGene Therapy May Allow Hemophilia Patients to Go Without MedsThyroidectomy-Specific Quality Improvement Measures ID'dPatients OK With Fewer Opioids After Gallbladder SurgeryShhhh! Patients Are SleepingDiagnostic Mutations ID'd in Chronic Kidney Disease PatientsAntithrombotics Deemed Safe in Carpal Tunnel Release SurgeryLink Between Diabetes, Antibiotic Use Called Into QuestionHealth Tip: Diagnosing PneumoniaNoisy Commutes Could Cause Long-Lasting DamageThe Buzz on How Flies Spread DiseaseRisk of Surgical Complications Up for Overlapping Hip SurgeryOral Microbiome Composition Linked to Esophageal Cancer RiskSmartphone Pics Help Docs ID Kids' Skin ConditionEven Non-Heart Surgery May Harm Your HeartCan Scrotal Vein Condition Hike Heart Risks?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Vi-Tetanus Toxoid Conjugate Vaccine Can Prevent Typhoid


HealthDay News
Updated: Sep 29th 2017

new article illustration

FRIDAY, Sept. 29, 2017 (HealthDay News) -- A Vi-tetanus toxoid conjugate vaccine is efficacious for prevention of typhoid fever, according to a study published online Sept. 28 in The Lancet.

Celina Jin, M.B.B.S., from the University of Oxford in the United Kingdom, and colleagues examined the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established human infection model of Salmonella enterica serovar Typhi (S Typhi). Healthy adult volunteers (aged 18 to 60 years) were recruited and randomized in a 1-to-1-to-1 ratio to receive a single dose of Vi-conjugate (Vi-TT; 37 participants), Vi-polysaccharide (Vi-PS; 35 participants), or control meningococcal vaccine (31 participants). Participants orally ingested S Typhi and were assessed with daily blood culture over a two-week period.

The researchers found that 77, 35, and 35 percent of participants in the control, Vi-TT, and Vi-PS groups met the composite criteria for typhoid diagnosis, respectively, giving vaccine efficacies of 54.6 and 52 percent for Vi-TT and Vi-PS. In Vi-TT and Vi-PS participants, seroconversion was 100 and 88.6 percent, respectively; Vi-TT vaccine recipients had significantly higher geometric mean titers detected one month post-vaccination.

"Vi-TT is a highly immunogenic vaccine that significantly reduces typhoid fever cases when assessed using a stringent controlled model of typhoid infection," the authors write. "Vi-TT use has the potential to reduce both the burden of typhoid fever and associated health inequality."

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text
Editorial